












































Histone deacetylase inhibitors (HDACi) represent an 
emerging class of anticancer treatments. The most 
prominent one, suberoylanilide hydroxamic acid 
(SAHA, vorinostat, Zolinza) was the first one to be 
approved by Food and Drug Administration (FDA) for 
the treatment of cutaneous T-cell lymphoma [1], 
followed by romidepsin [2], and others like LBH589 
and valproic acid are in clinical trials [3].  Apart from  
 
 











































their autonomous antitumor capacity, these drugs have 
been reported to be synergistic with a number of 
commonly-used anticancer agents, further signifying 
their potential as therapeutic agents [4].  
 
HDACi act partially by inhibiting histone deacetylases, 
thus inducing the acetylation of histones. This 
modification renders chromatin in an active “open” 
state that allows accessibility to the transcriptional 
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action for these drugs, it has been demonstrated that 
these agents lead to acetylation of many non-histone 
factors including transcription factors, chaperones, 
DNA repair proteins and structural proteins [6]. These 
novel HDACi substrates which are involved in a wide 
range of signaling pathways and regulate a diverse array 
of biological processes, also partially contribute to the 
anticancer effects of these drugs. 
 
One of the signaling pathways known to be activated by 
multiple stimuli is the one that converges on eIF2α 
phosphorylation [7]. This modification renders eIF2α 
from a substrate of the guanine-nucleotide exchange 
factor, eIF2B, to its inhibitor [8], which subsequently 
leads to an inhibition of mRNA translation. The general 
“shutdown” of protein synthesis provides the cell an 
opportunity to respond to the stress, and can act either 
by facilitating or protecting from cell death. This 
decision on cell fate mainly depends on the type and 
duration of the stress [9;10].  
 
The kinases that phosphorylate eIF2α belong to a family 
of four members and are activated by different kind of 
stimuli; the interferon-inducible protein kinase R (PKR) 
in response to dsRNA, the endoplasmic reticulum (ER)-
resident kinase (PERK) by accumulation of unfolded 
proteins in the ER, the general amino acid 
nonderepressing kinase 2 (GCN2) in response to 
aminoacid starvation, and the heme-regulated inhibitor 
(HRI) by low levels of heme or iron [8]. While it is 
believed that the kinases act mainly by modulation of 
the translation machinery, other functions unrelated to 
this specific mode of action have been described for 
PKR, PERK and GCN2 [11-13]. 
 
The contribution of the eIF2α phosphorylation pathway 
in the response to HDACi has not been thoroughly 
explored. In the few examples present in the literature, 
it has been demonstrated that treatment of the 
eosinonophilic leukemic cell line Eol-1 with HDACi 
leads to differentiation of these cells to mature 
eosinophils. This transformation to a differentiated state 
was attributed to a downregulation of the oncogenic 
fusion protein Fip1-like1-platelet-derived growth factor 
receptor alpha (FIP1L1-PDGFRA), whose mRNA 
translation was blocked by an induction in eIF2α 
phosphorylation [14-16]. In a recent study, PERK was 
shown to promote apoptosis in response to vorinostat in 
the U251 glioblastoma cell line through undefined 
mechanisms [17]. Moreover eIF2α phosphorylation was 
induced in response to paraborinostat in MCF-7 breast 


























































Figure  1.  eIF2α phosphorylation  is  induced  in  human
cancer and mouse cells upon treatment with vorinostat.
(A)  A549,  HT1080  and  HepG2  cells  were  treated  with  DMSO






DMSO  (con)  or  10 μM  of  vorinostat  (SAHA)  for  the  indicated
time periods. Protein extracts (50 μg) were subjected to western
blot analysis for phosphorylated eIF2α (panel a) and total eIF2α
(panel  b).  Representative  blots  are  shown.  The  ratio  of  the
phosphorylated  protein  to  total  normalized  to  its  control  is
indicated.  Quantification  of  the  bands  was  performed  by
densitometry using the Scion Image software. 
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only induced in response to vorinostat treatment but 
also protects against the cytotoxic effects of this agent. 
Furthermore, this modification is a combinatorial event, 
involving more than one of the eIF2α kinases. More 
interestingly, PKR and GCN2 were found to enhance 
the sensitivity of the cells to this HDACi, thus opposing 




eIF2α phosphorylation is induced in human cancer 
and mouse cells upon treatment with vorinostat 
 
An earlier report has shown that in response to 
vorinostat treatment, eIF2α phosphorylation is induced 
in the U251 glioblastoma cell line [17]. We wished to 
examine if this upregulation is a general phenomenon 
met in human cancers. To this end we treated A549 
lung carcinoma, HT1080 fibrosarcoma and HepG2 
hepatocarcinoma cells with this drug and observed an 
increase in the levels of phosphorylated eIF2α at all 
time points examined (Figure 1A). To extend our study 
we also treated mouse embryonic fibroblasts (MEFs) 
with vorinostat, where we observed a similar 
upregulation in eIF2α phosphorylation. As control for 
eIF2α phosphorylation, we used MEFs that cannot be 
phosphorylated on Ser51, due to a mutation of Ser to 
Ala (eIF2α
 A/A), alongside their wildtype counterpart 
MEFs (eIF2α
 S/S) (Figure 1B). Taken together, we 
conclude that activation of the eIF2α phosphorylation 
pathway upon treatment with this agent is a common 
phenomenon observed both in human and mouse cells.  
 
Multiple eIF2α kinases are responsible for the 
induction of eIF2α phosphorylation upon treatment 
with vorinostat 
 
Next we wished to determine which of the eIF2α 
kinases is responsible for mediating eIF2α phospho-
rylation in response to vorinostat. To this end, we 
treated MEFs deficient in each of the four eIF2α kinases 
together with their isogenic wildtype MEFs with the 
chemotherapeutic agent and examined eIF2α 
phosphorylation. Consistent with the previous findings, 
we detected an induction of eIF2α phosphorylation in 
all MEFs examined. However, even though the induc-
tion of eIF2α phosphorylation was lower in the 
knockouts (KO) of PERK, GCN2 and HRI compared to 
their isogenic wildtype cells (WT), it was not 
completely abolished in any of them, suggesting that 
vorinostat can activate more than one of the eIF2α 
kinases (Figure 2A). The redundancy of the eIF2α 



































































with  their  isogenic  control  (WT)  with  DMSO  (con)  or  10 μ M
vorinostat  (SAHA)  for  the  indicated  time  periods.  Protein
extracts  (50 μ g)  were  subjected  to  western  blot  analysis  for
phosphorylated  eIF2α  (panel  a)  and  total  eIF2α  (panel  b).
Representative blots are shown. The ratio of the phosphorylated
protein  to  total  normalized  to  its  control  is  indicated.
Quantification  of  the  bands  was  performed  by  densitometry
using the Scion Image software. 
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  (DKO) where the 
upregulation of eIF2α phosphorylation was only 
partially diminished in the absence of the two kinases 
(Figure 2B), further indicating that the induction 
observed, is a combinatorial event involving multiple 
kinases. 
 
eIF2α phosphorylation protects against vorinostat-
induced cell death 
 
It is established in the literature that eIF2α 
phosphorylation can play both cytoprotective or 
proapoptotic roles depending on the type and duration 
of stress [10;20]. Here, we wished to investigate the 
effect of eIF2α phosphorylation in respect to cell fate 
upon treatment with vorinostat. To this end, we treated 
eIF2α
 S/S and eIF2α
  Α/Α MEFs with this drug and 
measured the cell death index by FACS analysis using 
propidium iodide (PI) staining. Our data show that 
eIF2α
  Α/Α MEFs are more sensitive to this drug than 
eIF2α
 S/S MEFs, indicating that eIF2α phosphorylation 
protects against vorinostat-induced cell death (Figure 
3A). In order to confirm the FACS analysis data we 
examined the levels of cleaved caspase 3, a downstream 
effector of apoptosis. We observed high levels of 
cleaved caspase 3 in the treated eIF2α
  Α/Α MEFs, in 
contrast to the treated eIF2α
 S/S MEFs where cleaved 
caspase 3 was almost not detectable (Figure 3B). To 
extend our observations to human cells, we treated 
HepG2 cells with vorinostat together with a derivative 
of salubrinal [21], sal003, a compound that increases 
phosphorylation of eIF2α by blocking its 
dephosphorylation. Treatment with both agents 
decreased the cell death index in the co-treated cells 
compared to the cells treated only with the HDACi 
(Figure 3C), further validating that eIF2α 
phosphorylation protects from the apoptotic effects of 
the drug not only in mouse but also in human cells. 
 
eIF2α kinases enhance sensitivity to vorinostat 
independently of eIF2α phosphorylation 
 
We have previously demonstrated that the eIF2α kinase 
PKR can promote doxorubicin-induced apoptosis in an 
eIF2α independent manner [22]. In order to examine if 
the biological effect of the eIF2α kinases in response to 
vorinostat is mediated by eIF2α phosphorylation or is 
independent of it, we treated wildtype and knockout 
MEFs of each of the four kinases with this drug and 
subjected them to FACS analysis. In contrast to the 
observation that eIF2α phosphorylation was 
cytoprotective, GCN2 and PKR significantly  increased  
the sensitivity of the cells to the HDACi  (about 40% in  
 
 
both cases) as indicated by the differences in the cell 
death index between the wildtype and knockout MEFs. 
A similar trend but to a much lesser extent was 
observed in HRI
 +/+ and HRI 
-/- MEFs. On the contrary 
no significant differences in SAHA induced-
cytotoxicity were observed in PERK 
+/+ and PERK 
-/- 
MEFs (Figure 4A).  
 
Further we wished to investigate whether this 
proapoptotic effect is specific to vorinostat or if it takes 
place with other HDACi. To this end, we treated GCN2 
+/+  and GCN2
 -/- MEFs with trichostatin A (TSA), a 
structurally and functionally similar HDACi to 
vorinostat, and nicotinamide, a molecule that targets 
HDAC family members that are not inhibited by 
vorinostat or TSA. Similar to what we observed for 
vorinostat, these two compounds were more cytotoxic 
in the presence of GCN2 (Figure 4B). Taken together, 
these data support that in response to HDAC inhibition 
the eIF2α kinases mediate a proapoptotic role 




In this study we report that eIF2α phosphorylation is 
increased upon treatment with vorinostat and that this 
induction is a common phenomenon observed both in 
human and mouse cell lines. While the biological effect 
of this modification is to enhance the resistance of cells 
to this agent, PKR and GCN2 confer an opposite 
phenotype, promoting vorinostat-induced cytotoxicity. 
Considering that certain cancers don’t readily respond to 
HDAC inhibition and that some malignancies that 
initially respond to these treatments will develop 
resistance [23], it is essential to determine the factors that 
contribute to chemosensitivity and those which prevent 
chemotherapeutics from exerting their cytotoxic effects. 
 
HDACi can promote cell death through a variety of 
ways [24]. Although the pathways that link eIF2α 
phosphorylation to the apoptotic program are well 
understood [7], little is known about how can eIF2α 
kinases activate cell death pathways independently of 
eIF2α phosphorylation. We have previously established 
that PKR can promote doxorubicin-induced apoptosis 
through JNK in a eIF2α independent fashion [22]. 
Moreover, PKR has been demonstrated to physically 
interact with Fas-associated protein with death domain 
(FADD) [25] and inhibitor of kappa B kinase (IKK) 
[26], the latter protein mediating the tumor necrosis 
factor (TNF) induced response [27], further linking this 
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 An important question that needs to be addressed is how 
the HDACi activate the eIF2α kinases. One possibility 
is that they do so by altering the interactions between 
eIF2α kinases with chaperones. It has been demon-
strated that all of the eIF2α kinases are held in a 
dormant state through their interaction with chaperones 
and treatment with geldanamycin, an agent that changes 
the conformation of hsp90 chaperone, regulates the 
activity of PKR [28], GCN2 [29] and HRI [30]. To 
support this notion, HDACi have been shown to lead to 
the acetylation of heat shock protein 90 (hsp90), 
resulting in the subsequent release of its client poteins 
like the breakpoint cluster region-abelson fusion protein 
(Bcr-abl) [31], and acetylation of the ER-resident 
chaperone glucose-regulated protein 78 (GRP78), 
leading to activation of PERK [17]. Therefore it is 
highly plausible that acetylation of these chaperones by 
vorinostat orchestrates the simultaneous activation of all 
the eIF2α kinases in the cell. This is not the first report 
showing that anticancer agents lead to the parallel 
activation of multiple eIF2α kinases. Flavonoids, which 
intriguingly can also modulate hsp90 function and 
levels [32;33], have also been demonstrated to 
simultaneously activate HRI, PKR and PERK [34], 
further indicating the need to characterize the 
mechanisms of eIF2α kinase activation in response to 
chemotherapeutics. 
 
In conclusion this study unveils the contribution of the 
eIF2α phosphorylation pathway in the biological 
outcome to vorinostat treatment. We have demonstrated 
the involvement of eIF2α phosphorylation as a 
cytoprotective mechanism against this agent. In 
contrast, we show that the eIF2α kinases display 
divergent roles which oppose the cytoprotective effect 
of eIF2α phosphorylation. Although GCN2 expression 
has not been documented so far to be increased in any 
malignancy, PKR levels and/or activity have been 
reported to be elevated in breast cancer [35], melanoma 
and colon cancer cell lines [36] and hematological 
malignancies [37], raising the possibility that these 
cancers might be good candidates for treatment with 
these agents. The proapoptotic effects of these kinases 
to HDAC inhibition could be further augmented in 
cancers where eIF2α phosphorylation effects on 
translation are counteracted by overexpression of eIF2Β 
[38]. Furthermore HDACi could be used in combination 
with strategies that block this phosphorylation such as 
expression of eIF2α mimetic proteins like the hepatitis 
C virus (HCV) E2 protein [39] or proteins that induce 
eIF2α dephosphorylation like human papillomavirus 
(HPV) E6 protein [40]. As such the eIF2α 
phosphorylation pathway could be exploited to improve 
the treatment with HDACi. 
METHODS 
 
Cell culture and treatments. MEFs deficient in each of the 
four eIF2α kinases or deficient in eIF2α phosphorylation 
were maintained as previously described [11]. GCN2 
-/- 
PERK 
-/-  MEFs and their wildtype counter-parts were 
cultured as previously described [41]. HT1080 and A549 
cells were grown as previously described [10]. HepG2 
cells were maintained as previously described [42]. Cells 
were treated with 10 μM of vorinostat (ChemieTek, 
Indianapolis, IN, USA) dissolved in DMSO, 20 μΜ of 
sal003 (ChemBridge, San Diego, CA, USA) dissolved in 
DMSO, 1 μM trichostatin A (Sigma, Oakville, ON, 
Canada) dissolved in DMSO or 50 mM nicotinamide 
(Sigma) dissolved in H2O. The controls were treated with 
an equal amount of the solvent.  
 
Cell staining and flow cytometry analysis. FACS 
analysis using propidium iodine staining was performed 
as previously described [40]. 
 
Protein extraction and immunoblotting. Extraction of 
proteins from cells and western blot analysis were 
performed as previously described [40]. For 
immunoblotting of cleaved caspase 3 extracts were 
prepared as previously described [43]. The antibodies 
used in this study are previously described in [22]. 
 
Statistical analysis. All quantitative variables are 
presented as means ± S.E.M. We compared the 
differences of more than two groups using one-way 
ANOVA and the differences of two groups using two-
tailed Student t test (GraphPad Prism 5, La Jolla, CA, 
USA), and P<0.05 was considered statistically 
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